(firstQuint)Study to Evaluate Diphenhydramine in Children and Adolescents.

 This study has an open-label, single-dose classical pharmacokinetic design with no comparator treatment or group.

 Twenty-four (24) children, ages 2 to < 12 years, and 12 adolescents, ages 12 to < 18 years, with symptoms due to hay fever or other upper respiratory allergies will complete the study.

 To ensure that younger children are represented, at least 35% (8) of the children enrolled will range from 2 to < 6 years of age.

.

 Study to Evaluate Diphenhydramine in Children and Adolescents@highlight

To characterize the pharmacokinetics of diphenhydramine in two pediatric populations: children, ages 2 to < 12 years, and adolescents, ages 12 to < 18 years.

